Legislative language in the federal appropriations package would create a streamlined Medicare coverage pathway for multi‑cancer early detection (MCED) tests following FDA approval, according to reporting. If enacted, the provision would allow Medicare reimbursement for FDA‑cleared MCEDs without prior U.S. Preventive Services Task Force endorsement and peg payment to an existing multianalyte stool DNA rate ($509) beginning in 2029, with phased eligibility by age. The change addresses a major commercial barrier for MCED companies, which have argued that USPSTF review timelines have hindered reimbursement access for innovative blood‑based cancer screening tests. Analysts noted variation in impact across MCED players depending on existing product portfolios and current reimbursement arrangements. Stakeholders in diagnostics and oncology welcomed the policy as a potential accelerator for clinical adoption and trial enrollment for screening studies, while payers and policy observers flagged implementation and budget implications that will shape final negotiations.